Products
Adimanebart Biosimilar Monoclonal Antibody (MuSK) for Research
Cat No.: GMP-Bios-INN-1067
Anti-MUSK therapeutic antibody (Pre-made Adimanebart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Adimanebart (development code ARGX-119) is a humanized monoclonal antibody agonist targeting muscle-specific kinase (MUSK). It is developed by argenx for congenital myasthenic syndrome. It is in Phase III clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1067-1mg | 1mg | 3090 |
| GMP-Bios-INN-1067-10mg | 10mg | |
| GMP-Bios-INN-1067-100mg | 100mg | |
| GMP-Bios-INN-1067-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Adimanebart biosimilar, Whole mAb, Anti-MUSK Antibody: Anti-MUSK/Muscle/skeletal receptor tyrosine-protein kinase/Muscle-specific tyrosine-protein kinase receptor (MuSK therapeutic antibody |
| INN Name | Adimanebart |
| Target | MUSK |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | TBC |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2025 |
| Year Recommended | na |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | TBC |
